Respiratory ATP synthesis: The new generation of mycobacterial drug targets?

  • Bald D
  • Koul A
  • 69


    Mendeley users who have this article in their library.
  • 51


    Citations of this article.


Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs.

Author-supplied keywords

  • ATP synthesis
  • Antimycobacterial drugs
  • Dormancy
  • Mycobacteria
  • Respiratory chain

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Dirk Bald

  • Anil Koul

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free